Exelixis Inc SEC Filings

EXEL filed a Form 144 notice reporting proposed transactions in Common stock tied to compensation activity. The filing lists 3,856 shares related to restricted stock vesting on 01/05/2026 and 3,856 shares from option exercises on 05/07/2026, with trades to be handled through Morgan Stanley Smith Barney LLC on NASDAQ.

EXEL reported a notice of proposed sale of securities: the filing lists a proposed sale of 60,000 shares of Common Stock and an aggregate amount of $2,742,468.00, with 251,355,083 shares shown on the same line and the date 05/07/2026. The schedule itemizes multiple tranches of restricted stock vesting under a registered plan with specific vesting dates and share counts (examples: 3,457; 3,458; 15,538). The notice is a routine Form 144 disclosure by an affiliate identifying securities to be sold under a registered plan.

Exelixis, Inc. reported strong first‑quarter 2026 growth, driven mainly by its cabozantinib franchise. Total revenues rose to $610.8 million from $555.4 million a year earlier, with net product revenues increasing to $555.0 million. Net income climbed to $210.5 million, up from $159.6 million, and diluted EPS improved to $0.79 from $0.55, reflecting operating leverage as total operating expenses stayed roughly flat.

The company ended the quarter with $1.43 billion in cash, cash equivalents and marketable securities and continued returning capital to shareholders, repurchasing common stock for $430.4 million of cash in the quarter as part of a broader buyback program. Exelixis also highlighted progress in its oncology pipeline, including zanzalintinib, which has an FDA‑accepted New Drug Application in metastatic colorectal cancer and multiple ongoing pivotal and phase 2 studies across several tumor types.

Exelixis reported strong first quarter 2026 results and expanded its stock repurchase plans. Total revenues were $610.8 million, up from $555.4 million a year earlier, driven by net product revenues of $555.0 million, largely from the U.S. cabozantinib franchise. GAAP net income was $210.5 million, or $0.79 per diluted share, while non-GAAP diluted EPS was $0.87.

The company reaffirmed 2026 guidance, including total revenues of $2.525–$2.625 billion and net product revenues of $2.325–$2.425 billion, with an effective tax rate of 21–23%. Exelixis’ board authorized a new $750 million stock repurchase program through December 31, 2027, after repurchasing $590.6 million under its October 2025 program and $2.59 billion cumulatively since March 2023, retiring 86.8 million shares.

Pipeline momentum continued as the FDA accepted the NDA for zanzalintinib in previously treated metastatic colorectal cancer, with a PDUFA target action date of December 3, 2026. Multiple pivotal trials, including STELLAR-303, STELLAR-304, STELLAR-311, STELLAR-316 and Merck’s LITESPARK-033 and -034, are underway or planned across colorectal, renal cell, neuroendocrine and other tumors.

Exelixis Inc Schedule 13G shows Vanguard Capital Management reported beneficial ownership of 13,233,247 shares of common stock, representing 5.09% of the class. The filing states Vanguard has sole dispositive power over 13,233,247 shares and sole voting power over 1,974,263 shares.

The filing lists Vanguard affiliates and clarifies holdings include shares held for funds and managed accounts. The form is signed by Vanguard's Head of Global Fund Administration on 04/29/2026.

Exelixis, Inc. calls a virtual 2026 Annual Meeting on May 26, 2026, asking stockholders to elect eleven directors, ratify Ernst & Young LLP as auditor, approve a 2,000,000‑share increase to the 2017 Equity Incentive Plan, and give an advisory Say‑on‑Pay vote.

The company highlights 2025 as its ninth consecutive year of operating profitability, with total revenue of $2.32 billion, up 7% year over year, driven by the cabozantinib franchise. Exelixis filed its first New Drug Application for zanzalintinib, accepted for FDA review in early 2026, and continued pivotal trials.

Management emphasizes disciplined capital allocation, including share repurchases, and a one‑time broad‑based equity grant to reinforce ownership culture and retention. The proxy details board composition, committee structure, director independence, and extensive governance, risk oversight and compensation frameworks aligned to long‑term oncology growth.

Exelixis Inc ownership disclosure: The Vanguard Group filed an amendment stating it beneficially owns 0 shares of Exelixis common stock, representing 0% of the class. The filing notes an internal realignment on January 12, 2026 and cites "in accordance with SEC Release No. 34-39538 (January 12, 1998)."

The filing is signed by Ashley Grim, Head of Global Fund Administration, and lists The Vanguard Group's address in Malvern, Pennsylvania.

Aftab Dana reported acquisition or exercise transactions in this Form 4 filing.

EXELIXIS, INC. executive vice president of research and development Dana Aftab reported an equity compensation grant in the form of restricted stock units (RSUs). The award covers 52,018 shares of common stock, granted under the company’s 2017 Equity Incentive Plan at no cash cost.

These RSUs will vest as to one quarter of the original grant on May 15, 2027, and one quarter on each following May 15 until fully vested. Following this grant, Aftab’s directly held common stock position, including previously granted RSUs and performance-based RSUs, totals 668,124 shares, of which 466,061 shares relate to unvested RSUs and a prior performance-based award. In addition, 5,835 shares are held indirectly through the Exelixis 401(k) Plan as of a statement dated February 26, 2026.